Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
GLP-1RAs are attractive candidates for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) because they can reduce body weight and improve insulin secretion [77]
AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress [2]
Regarding metabolic regulation, hepatocyte growth factor (HGF) secreted by MenSCs downregulates hepatic Rnf186 expression and modulates the AMPK-mTOR signaling pathway, improving glucose and lipid metabolism
Younossi ZM, Stepanova M, Lawitz E, et al
US$ 27.86
US$ 29.27
US$ 20.78
US$ 28.33
US$ 23.25
US$ 23.66
US$ 26.92
US$ 24.92
